Novartis Signs MOU To Invest $100 Million In R&D, Exchanges With Korean Scientists By 2013
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Novartis signed a memorandum of understanding with Korea's Ministry for Health, Welfare and Family Affairs to invest $100 million (KRW 125 billion) over the next five years in the research and development of new drugs, scientific exchanges and collaboration in the life sciences
You may also be interested in...
Korea, Switzerland Ink MOU To Combine Talents In Pharma, Medical Devices
In a bid to bolster their respective health care industries, South Korea and Switzerland signed an MOU to cooperate on life sciences investments by combining Switzerland’s knowhow in precision machinery, nanotechnology and biotechnology with Korea’s expertise in manufacturing technology.
Sanofi Looks To Build Stronger Alliances To Fuel R&D In Korea
Marking the conclusion of a 2009 MOU, Sanofi signed a letter of intent with the Korean government to take R&D investments to a new level.
Novartis Venture Fund Supporting Korea's Bio Start-ups
Series B financing for the fund's first investment is seen by Novartis as validation for discovery efforts.